Sessa Capital (Master), L.P. has filed 5 insider transactions across 1 company since July 2025.
Most recent transaction: a option exercise of 1740000 shares of SAB Biotherapeutics, Inc. ($SABS) on September 29, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 29, 2025 | SAB Biotherapeutics, Inc. | $SABS | Sessa Capital (Master), L.P. | Director | M | Common Stock | 1740000 | $1.75 | 2,198,457.0000 | 9,261,918 | 379.53% | 18.79% |
| Sept. 29, 2025 | SAB Biotherapeutics, Inc. | $SABS | Sessa Capital (Master), L.P. | Director | M | Series B Convertible Preferred Stock | 17400 | $0.00 | 211,100.0000 | 9,261,918 | 7.61% | 0.19% |
| July 22, 2025 | SAB Biotherapeutics, Inc. | $SABS | Sessa Capital (Master), L.P. | Director | A | Series B Convertible Preferred Stock | 228500 | $0.00 | 228,500.0000 | 9,261,918 | 9999.99% | 2.47% |
| July 22, 2025 | SAB Biotherapeutics, Inc. | $SABS | Sessa Capital (Master), L.P. | Director | A | Warrants (right to buy) | 228500 | $0.00 | 228,500.0000 | 9,261,918 | 9999.99% | 2.47% |
| July 22, 2025 | SAB Biotherapeutics, Inc. | $SABS | Sessa Capital (Master), L.P. | Director | A | Warrants (right to buy) | 114250 | $0.00 | 114,250.0000 | 9,261,918 | 9999.99% | 1.23% |